Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY / ABSTRACT Vaccines have been very effective at protecting against infectious diseases that pose serious threats to human health, but they can also be limited if the pathogens demonstrate antigenic drift, as is the case for influenza. This genetic drift causes mismatches between antigens in the vaccines vs. in the circulating strains, resulting in vaccines that lose neutralization potency against the new variants. Recent studies have shown that the release kinetics of vaccines can be important in establishing lasting and efficacious immunity. In particular, extending the exposure time to antigens can result in higher antibody titers and increase the breadth of neutralizing antibodies that target a broader range of epitopes (relative to conventional bolus vaccination). This can prevent the concern of low vaccine potency after viral mutations. To develop a single-administration vaccine platform based on these premises, we use a H5N1 avian influenza virus model, a pathogen for which the human population currently does not have existing immunity. We have shown that combining the effects of nanoparticles to effectively present H5 hemagglutinin antigen, together with slow release from a thermo-responsive PLGA- PEG-PLGA polymer depot to give extended antigen exposure, will elicit increased durability of the immune response, a broader cross-reactivity for viral variants, and protection from H5N1 infection. Many questions still remain, however, regarding the mechanisms by which this is accomplished and the optimization of this nanoparticle-hydrogel vaccine platform. Our specific aims are to: (1) determine optimized conditions for a nanoparticle-hydrogel vaccine platform and understand the contributing factors of their immune effects, (2) broaden cross-reactivity by incorporating antigens into nanoparticle-hydrogel vaccines that will generate homosubtypic and heterosubtypic responses, and (3) evaluate the cross-reactive and protective effects of combined, optimized vaccine elements. Because these vaccines are modular, and different antigens can be exchanged in a relatively straightforward approach, the successful implementation of this proposed strategy would have wider applicability towards the development of vaccines for other infectious pathogens and for universal flu vaccines.
Grant Summary
Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $721K for university, nonprofit, healthcare org. Applications are due 2031-03-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $721K
2031-03-31
- 1Confirm your organization is eligible for Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines: Frequently Asked Questions
Who is eligible for the Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines?
Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines provide?
Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines provides up to $721K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines deadline?
Applications for Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines are due 2031-03-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines?
To apply for Increasing Breadth of Immune Response by Single-Dose Influenza Vaccines, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.